Insilico now has a pipeline of more than 40 AI-developed drugs it is developing for conditions such as cancer, bowel and kidney disease.

Many in the AI community believe that the next major revolution will be the era of self-improving AI where AI can improve ...

Information pervades the universe, yet means nothing. Meaning emerged when matter organized into systems that could ...

You are about to hear a lot more about Claude Code.

Researchers have developed a machine learning model capable of predicting whether a patient with depression will respond to ...

Serious computer scientists are increasingly believing that humans will no longer be required to write any code. The latest ...

While standard models suffer from context rot as data grows, MIT’s new Recursive Language Model (RLM) framework treats ...

Ricursive Intelligence, founded by two former Google researchers and valued at $4 billion, is among several efforts to ...

Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.

Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across diverse ...

For decades, artificial intelligence advanced in careful, mostly linear steps. Researchers built models. Engineers improved performance. Organizations deployed systems to automate specific tasks. Each ...